
SESSION 2 POSTER PRESENTATION

THURSDAY 22 SEPTEMBER

Pharmacovigilance of biologics originator and biosimilar

P045 Does Omalizumab Increase the Risk of Malignancy? A Retrospective Case-Control Study in a Single Tertiary Hospital

Kim Hyun Jee, Seoul National University Hospital, Republic of Korea

Risk communication

P194 Pfizer-BioNTech COVID-19 Vaccine Associated Risk of Olfactory Hallucinations-Signal Review

I Fouda Mohammed , SFDA, Saudi Arabia

P195 Effect of Direct Healthcare Professional Communication on Citalopram and Escitalopram

Köberle Ursula, Drug Commission of the German Medical Association, Germany

P196 Regulatory Action Following Dextromethorphan Misuse in Adolescents in the Czech Republic

Deščíková Veronika, State Institute for Drug Control, Czech Republic

P198 Survey on Pharmacovigilance Knowledge and Activities in Sardinia

Sanogo Seydou, ARES – Sardegna, Italy

P201 Patch Tests and Cross-Reactivity Among Antiepileptic Drugs

Salvo Francesco, Universite de Bordeaux, France

P202 Stevens-Johnson Syndrome Induced by Lidocaine at the University Hospital of Libreville in Gabon: A Case Report

Ntoutoume Nzoghe Pierre Constant, Faculty of Medicine and Pharmacy Rabat, Morocco

P203 Experience in Communicating Vaccine Side Effects in a Covid-19 Population Vaccination Centre in North-East Italy

Montesarchio Livio, University of Verona, Italy

P205 Impact of Risk Communication on the Number of Pharmacovigilance ICSRs in Brazil

Capucho Helaine, Brazilian, Brazil

P206 Digital Risk Minimization Measures: Qualitative Feedback from Healthcare Professionals in Egypt

Rostom Hadir, ISoP Egypt Chapter – MSA University, Egypt

- 
-
- P207** Risk Communication about Medicines: Initiatives for improving in Saudi Arabia
Alowedi Nada, Saudi Food and Drug Authority, Saudi Arabia
-
- P208** Risk Communication: Ensuring an Appropriate Benefit Risk Ratio in the Safety Profile of a Medicinal Products in Ghana
Owusu Ronald Aboraah, Pokupharma Limited, Ghana
-
- P209** Decision Tree to Distinguish Important Urgent Safety Concern Types and Other Safety Concerns to Fulfill Reporting Requirements
Kaehler Stefan, Bristol Myers Squibb, Austria
-
- P210** Evolving Global Requirements for Signal Notification to Health Authorities: How to Standardize and Harmonize Signal Communication
Privot Fanny, BMS, France
-

Database networks for post-marketing surveillance for vaccines and medicines

- P215** Riluzole Prescribing Beyond Therapeutic Indications in Clinical Practice
Crescioli Giada, University of Florence, Italy
-
- P216** A Safety Profile Analysis of Adverse Events After Measles-Mumps-Rubella and Varicella Immunization Based on Italian Pharmacovigilance Network in Veneto Region
Soriolo Nicola, University of Verona, Italy
-
- P217** The Case Review Vignette
Nagpal Sumit, USA
-
- P220** Expansion of VigiFlow® Network to a Third Level for Post-Marketing Surveillance of COVID-19 Vaccines in Iraq
Younus Manal, MOH, Iraq
-
- P222** Genital Itching and Other Genital Discomforts Associated with the Parenteral and Oral Clindamycin in Vigibase
Beltrán Cecilia, Pharmacovigilance and Technovigilance National Center of Peru, Peru
-
- P223** Monoclonal Antibodies Diseases Modifying Agents: A Drug Safety Surveillance Study in Patients with Multiple Sclerosis
Alghamdi Eman, Saudi Food and Drug Authority, Saudi Arabia
-
- P224** Adverse Events Related to Lutetium (177Lu) Oxodotreotide (Lutathera): "Real-Life" Data from the Eudra-Vigilance Database
Dal Mas Liana, Università degli Studi di Padova Dipartimento di Scienze del Farmaco, Italy
-

-
- P225** **A Retrospective Analysis of Adverse Drug Events Leading to Hospitalization or Prolonged Hospitalization in Saudi Arabia**
Alqadheeb Eman, SFDA, Saudi Arabia
-
- P226** **The Effect of the COVID-19 Vaccine on Menstruation and Hair loss Amongst the Saudi Population Using the National Reporting System**
Ablowi Fotoun, Saudi food and drug authority, Saudi Arabia
-
- P227** **Assessing the Post-Marketing Experience of Drug Ineffectiveness Reports Received by the Saudi Vigilance System**
Alolayet Rayan, Saudi Food and Drug Authority (SFDA), Saudi Arabia
-
- P228** **The Impact of Mobile Apps for Spontaneous Reporting: Experience from COVID-19 Vaccines Safety Surveillance**
Magro Lara, University of Verona, Italy
-
- P229** **Adverse Drug Reactions in Older People Reported to the Portuguese Pharmacovigilance System during 2019**
Herdeiro Maria Teresa, iBiMED – Instituto de Biomedicina Dpt. Ciências Médicas, Univ. Aveiro, Portugal
-
- P230** **Immune Checkpoint Inhibitors and Pregnancy: A Pharmacovigilance Analysis in VigiBase®**
Noseda Roberta, Institute of Pharmacological Sciences of Southern Switzerland, Switzerland
-
- P231** **Follow-up of Covid-19 Vaccinated Pregnant and/or Breastfeeding Women in Tunisia**
ElAidli Sihem, University of Tunis El Manar Faculty of Medecine of Tunis -UR17ES12, Tunisia
-
- P232** **Cutaneous Adverse Reactions Reported with Antiepileptic Drugs in Tunisian Pediatric Population**
El Aidli Sihem, Centre national de pharmacovigilance, Tunisia
-
- P233** **A Survey on the Adverse Drug Reactions of Covid-19 Vaccines Administered within the Local Health Authority of Verona**
Schmid Francesca, University of Padova, Italy
-
- P234** **Spontaneous Reports of Delayed Urticaria Following Booster Vaccination with Spikevax® in Switzerland**
Müller Laura, Institute of Pharmacological Sciences of Southern Switzerland, Switzerland
-
- P235** **Signal Detection by Disproportionality Analysis in the Monitoring of COVID-19 Vaccine Safety in Switzerland**
Noseda Roberta, Institute of Pharmacological Sciences of Southern Switzerland, Switzerland
-

- 
-
- P236** [Vitamin D-Induced Cardiovascular Toxicity: Preliminary Evidence from the FDA Adverse Event Reporting System \(FAERS\)](#)
Gringeri Michele, Università degli Studi di Milano, Italy
-
- P237** [Symptoms Potentially Related to Small Fiber Neuropathy \(SFN\) and Anticovid Vaccines](#)
Giannandrea Almagrazia, ASL BA, Italy
-
- P238** [Safety Profile of Antiviral Therapies for the Early Treatment/Prevention of COVID-19: Analysis of the International Pharmacovigilance Database VigiBase](#)
Bellitto Chiara, University of Verona, Italy
-
- P239** [Real-World Patterns and Trends of Idarucizumab Use in an Italian Region: A Probabilistic Record-Linkage Approach in the Period 2015-2020](#)
Lombardi Niccolò, University of Florence, Italy
-
- P240** [Antipsychotic Drugs Use in the Territory of the Central Tuscany Healthcare Authority – Preliminary Results of the ANTIGONE Project](#)
Crescioli Giada, University of Florence, Italy
-
- P241** [Herpes-Zoster Reactivation Following SARS-CoV-2 Vaccines](#)
Daghfous Riadh, Université Tunis el Manar Faculté de médecine de Tunis, Tunisia
-
- P242** [Cytolytic Hepatitis Following mRNA Vaccination](#)
Zaiem Ahmed, Université Tunis el Manar Faculté de médecine de Tunis, Tunisia
-
- P243** [Myocarditis Following SARS-CoV-2 Vaccines: A Series of Six Cases](#)
Daghfous Riadh, Université Tunis el Manar Faculté de médecine de Tunis, Tunisia
-
- P244** [Demonstration of TreeScan Techniques on a Federated Real-World Data Network](#)
Kundrot Steven, TriNetX, LLC, USA
-
- P245** [VAC4EU: A Pan-European Research Network For Collaborative Post-authorization Vaccine Safety And Benefit Monitoring](#)
Sturkenboom Miriam, UMC Utrecht, Netherlands
-
- P246** [Adverse Events Following HPV Vaccination in the Veneto Region: Data from Spontaneous Reporting](#)
Dalla Valle Diana, University of Verona, Italy
-
- P247** [Medicinal Cannabis and Related Products – Analyses of Quality Defects and Adverse Drug Reactions Reported by German Community Pharmacists](#)
Said André, Drug Commission of German Pharmacists (AMK), Germany
-

Clinical decisions in pharmacovigilance

- P249** [Gemcitabine-Induced Leukocytoclastic Vasculitis](#)
Zaiem Ahmed, National Center Chalbi Belkahlia of Pharmacovigilance, Tunisia
-
- P250** [A Dashboard to Visualize Adverse Events Data from the United States National Library of Medicine ClinicalTrials.gov Database](#)
Bond T. Christopher, Bristol Myers Squibb, USA
-
- P251** [Comparison of the Pathologic Complete Response of Pseudopolymorphic Forms of Docetaxel 80 mg in an Oncology Outpatient Clinic in Brazil](#)
Rialto Luiz Henrique, University of São Paulo, Brazil
-
- P252** [Strong Signs of Increased Number of Intoxications Following Rise in Prescription of Promethazine](#)
Thunander Sundbom Lena, Swedish Medical Products Agency, Sweden
-
- P253** [What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System](#)
Lunghi Carlotta, University of Bologna, Italy
-
- P254** [Risk of Psychotic Disorders Among Patients with Medical Cannabis Authorization: A Longitudinal Cohort Study](#)
Lunghi Carlotta, University of Bologna, Italy
-
- P255** [Assessing the Brighton Collaboration Case Definition of Sensorineural Hearing Loss in Ghana](#)
Sturkenboom Miriam, UMC Utrecht, Netherlands
-
- P258** [Safety and Tolerability of Dimethylfumarate, an Analysis of Pharmacovigilance Data Within the Region of Sardinia](#)
Anania Lorenzo, University of Cagliari, Italy
-
- P259** [Post-Marketing Safety of Anti-Calcitonin Gene Related Peptide Antibodies: A Disproportionality Analysis of the FDA Adverse Event Reporting System](#)
Giunchi Valentina, University of Bologna, Italy
-
- P260** [A Case Report of Possible Pembrolizumab-Induced Myasthenia Gravis from an Italian University Hospital: A Fatal Case Report](#)
Pivato Lisa, University Hospital of Padova, Italy
-
- P261** [The Approaches to Assess Robustness of Disproportionality Findings in Pharmacovigilance. A Meta-Epidemiological Research](#)
Fusaroli Michele, University of Bologna, Italy
-
- P262** [Paliperidone and Potential Risk of Hyponatremia](#)
Al-Fadel Nouf, Saudi Food and Drug Authority, Saudi Arabia
-

-
- P263** [Drug-Induced Acute Pancreatitis Cases Notified to the CNPV](#)
Jabri Fatma Ezahra, University of Tunis el Manar – Faculty of Medicine of Tunis:
research unit UR17ES12, Tunisia
-
- P264** [Personalized Approach to the Diagnosis and Treatment of Acute Psychoactive Substance Poisoning in Adolescents](#)
Zhdanova Olga, Voronezh State Medical University named after N. N.
Burdenko, Russian Federation
-
- P265** [Adverse Drug Events In an Intensive Care Unit: A Pilot Study Using the Global Trigger Tool](#)
Marília Berlofa Visacri, University of São Paulo, Brazil
-
- P266** [A Cross-Sectional Investigation for Verification of Falsified Medicinal Product in Egypt, Indicated by vials of Ampicillin/Sulbactam](#)
Ayman Yomna, MUP – Medical Union Pharmaceuticals, Egypt
-
- P267** [Erythema Multiforme Reactions Following Pfizer/BioNTech \(BNT162b2\) and Oxford/AstraZeneca \(chAdOx1-S\) COVID-19 Vaccination: A Case Series](#)
Charfi Ons, Université Tunis el Manar Faculté de médecine de Tunis /
Unité de recherche UR17ES12., Tunisia
-
- P268** [The Risk of Posterior Reversible Encephalopathy Syndrome with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases](#)
Velez-Nandayapa Luis, University of Basel / Novartis, Switzerland
-
- P269** [Evaluation Of Deprescribing Services In Frail Patients: A Systematic Review](#)
Alshatti Dalal, University of Birmingham, United Kingdom
-
- P270** [Using Real-World Data for Rapid Safety Investigations: Value of Near-Real-Time Clinical Data Querying](#)
Dimbil Mohamed, TriNetX, LLC, USA
-
- P271** [Localized Edema Occurring During Treatment with Risperidone](#)
Daghfous Riadh, Department for the collection and analysis of adverse
reactions, Tunisia
-
- P272** [The Risk of Myasthenia Gravis with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases](#)
Velez-Nandayapa Luis, University of Basel / Novartis, Switzerland
-
- P273** [Osteomalacia Following Rifampicin-Induced Hypovitaminosis D](#)
ELAidli Sihem, Centre national de pharmacovigilance, Tunisia
-
- P274** [Obinutuzumab and Non-Overt Disseminated Intravascular Coagulation: A Case Study of Signal Detection and Management in Italy](#)
Valdiserra Giulia, University of Pisa, Italy
-

-
- P276** **Pharmacovigilance of Cytotoxic Drugs in Childhood Cancer: A Retrospective Study**
Mousannif Soumaya, Faculty of Medicine and Pharmacy of Rabat, Morocco
-
- P277** **Photoallergic Eczema Induced by Fenofibrate**
Zaiem Ahmed, National Center Chalbi Belkahia of Pharmacovigilance, Tunisia
-
- P278** **Recurrent Erythema Multiforme with Paracetamol**
Zaiem Ahmed, National Center Chalbi Belkahia of Pharmacovigilance, Tunisia
-
- P279** **Assessment of Adverse Drug Reactions to Off-Label Drug Use in an Oncological Population Treated in a Northern Italian Hospital**
Berti Elena, ISTITUTO ONCOLOGICO VENETO IRCCS, Italy
-
- P281** **Interferon- β Induced Psoriasis in a Multiple Sclerosis Patient with Positive Rechallenge**
Zaiem Ahmed, Tunis el Manar University Faculty of Medicine of Tunis / Research Unit UR17ES12. Chalbi Belkahia National Centre for Pharmacovigilance, Tunisia
-
- P282** **Oxybutynin Induced Blidness in a Child**
Zaiem Ahmed, Tunis el Manar University Faculty of Medicine of Tunis / Research Unit UR17ES12. Chalbi Belkahia National Centre for Pharmacovigilance, Tunisia
-
- P283** **GRESIF: A Project for the Management of Severe Adverse Drug Reactions (SCARs). The Experience of Lombardy and Piedmont**
Pascale Giulia, ASST GOM Niguarda, Italy
-
- P284** **Adverse Events of Imatinib**
Aouitni Imen, Centre national de pharmacovigilance, Tunisia
-
- P285** **Carbamazepine-Acetazolamide Interaction Leading to an Hepatocellular Liver Injury: A Relevant Case Report**
Mansour Khadija, Department of Clinical Pharmacology, Tunisia

Ecopharmacovigilance

- P286** **Chronic Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Hormones on the Animal Model Danio Rerio**
Grisotto Jacopo, University of Verona, Italy
-
- P287** **The Value of International Pharmacovigilance Databases to Help Contain Antibiotic Resistance from a 'One Health' Perspective**
Mitchell Joseph, Uppsala Monitoring Centre, Sweden
-



Women's medicines

- P290** Medications use while breastfeeding – prevalence and attitude of women
Liiv Ekaterina, Almazov National medical research centre, Russian Federation
-
- P291** Comparative Safety of Metformin and Insulin in Gestational Diabetes – a Retrospective, Case-Control Study
Staynova Radiana, Medical University of Plovdiv, Faculty of Pharmacy, Bulgaria
-
- P293** Breastfeeding Women's Knowledge Toward Spontaneous Reporting of Adverse Drug Reactions – a Pilot Study from Bulgaria
Staynova Radiana, Medical University of Plovdiv, Faculty of Pharmacy, Bulgaria
-
- P295** Drug-Induced Liver Injury (DILI) and Ulipristal: A Cautionary Tale
Avó-Baião Rita, Faculdade de Medicina da Universidade de Lisboa, Portugal
-
- P296** Pharmacovigilance of Selective Serotonin Reuptake Inhibitors and Gender Differences in Stroke Incidence
Sellitto Carmine, University of Salerno, Italy
-
- P297** Safety of Painkillers during Pregnancy a Retrospective Analysis of Reports from the Italian Veneto Region and VigiBase
Rudolph Annette, University of Verona, Italy
-
- P298** Pharmacovigilance of Medicines for Controlled Ovarian Hyperstimulation – a Study of Patients' Perspective
Stoiev Svetoslav, Medical University Pleven, Bulgaria
-

Herbal and Traditional Medicines and dietary supplements

- P300** DNA Barcoding as a Tool to Overcome the Challenges of Phytovigilance of Natural Health Products Quality: The Example of Saffron
Skalli Souad, Faculty of Sciences Mohammed V University in Rabat, Morocco
-
- P301** "Title Case" = A case of Death Following the Application of "Nicotiana Glauca"
Rhaymi Chaimae, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
-
- P303** Surveillance of Suspected Adverse Reactions to Beehive Products
Ippoliti Ilaria, Istituto Superiore di Sanità, Italy
-
- P305** Improving the Knowledge Attitude and Practice of Pharmacovigilance Amongst Herbal Medicine Practitioners in Lagos
Oreagba Ibrahim, ACEDHARS University of Lagos, Nigeria
-
- P306** Safety of Therapies and Use of Supplements. The Pharmacy Clinical Desk Experience in the National Cancer Centre CRO Aviano
Baldo Paolo, Centro di Riferimento Oncologico CRO Aviano-IRCCS, Italy
-

Medical Device Safety

- P307** [The AOUI Verona Task Force for Improvement of Post-Market Clinical Surveillance for Medical Device](#)
Marini Paola, AOUI Verona, Italy
- P308** [Risk-Based Quality and Safety Management in Clinical Trials with Combination Devices in Changing Global Regulatory Environment](#)
Malikova Marina, Boston Medical Center, Boston University School of Medicine, USA
- P310** [Reported Health Problems Associated with the Use of Copper Intrauterine Devices](#)
Leonardo Alves Teresa, Dutch Reporting and Expertise Centre for Adverse Effects of Medical Implants (MEBI), Netherlands
- P311** [Insights into the Dutch Reporting and Expertise Centre for Adverse Effects of Medical Implants: A 5-Year Perspective](#)
Leonardo Alves Teresa, Dutch Reporting and Expertise Centre for Adverse Effects of Medical Implants (MEBI), Netherlands
-

Patient Engagement

- P314** [Consumer's Self-Assessment Form as a Source of COVID-19 Vaccine Surveillance Data in Iraq](#)
Al-Shimran Ban, Ministry of Health, Iraq
- P316** [First Patient Reports in Montenegro](#)
Vukicevic Veselinka, Institute for Medicines and Medical Devices, Montenegro
- P317** [Pharmacovigilance Evolution: Patient-Oriented Opportunities in Pharmaceutical Industry](#)
Facchinello Daniela, Roche S.p.A., Italy
- P319** [Patients' Attitudes Towards Deprescribing – A Cross-sectional Study in Older Patients in Romania](#)
Bucsa Camelia, Iuliu Hatieganu University of Medicine and Pharmacy, Romania
- P320** [Quasi-experiment Study on Use of Toll-free Phone Systems for Adverse Event Reporting by Patients and Clinicians](#)
Byomire - Ndagije Helen Byomire, National Drug Authority, Uganda
- P321** [Reporting ADR as a Citizen: Analysis of Data from Sardinian Region](#)
Ferrari Alessandra, Sardinia Regional Center of Pharmacovigilance, Italy
- P322** [Assessment of Safety of Use of Antismoking Drug Cytisine in a Hospital Setting](#)
Chiamulera Cristiano, University of Verona, Italy
-

- 
-
- P323** **Evaluating the Impact of Pharmaceutical Interventions on the Clinical Outcomes of Palliative Care Patients: A Single-Arm Clinical Trial**
Marques Cavalcante-Santos Lincoln, University of São Paulo, Brazil
-
- P324** **How Do You Find Monitored Dosage Systems?**
Stewart Leeanne, University of Birmingham, United Kingdom
-
- P325** **Are Pharmaceutical Companies Engaged with Patients for Pharmacovigilance? – A Search on Industry Accomplishment Regarding Patient Reporting of ADRs**
Matos Cristiano, Instituto Politécnico De Coimbra, ESTESC-Coimbra Health School, Portugal
-


Miscellaneous

- P328** **Spontaneous Reporting of Adverse Events Following Immunization in Veneto: Direct Transfer of Reports from the Local Vaccination Registry**
Schievano Francesco, University of Verona, Italy
-
- P329** **Am2P : A New Accredited Academic Training Program in Pharmacovigilance and Pharmacoepidemiology Designed for US, Canadian and Caribbean Healthcare Professionals**
Palin Karine, Université de Bordeaux, France
-
- P330** **Knowledge, Attitudes and Practices on Pharmacovigilance and Phytovigilance among students of MSc in Nursing Sciences**
Di Nolfi Annachiara, Italian National Institute of Health, Italy
-
- P331** **Children’s Pill School Evaluation: Healthcare Professionals’ Views and Recommendations**
Rashed Asia N, King’s College London, United Kingdom
-
- P332** **When the Drug Becomes Toxic! : Lyell Syndrome in a Moroccan Context**
Imane Zhim, Pharmacy Unit, Morocco
-
- P333** **ADHD Medication Use and Psychiatric Comorbidity, Trauma and Mortality in Children and Young Adults: A Cohort Study from Quebec, Canada**
Lunghi Carlotta, University of Bologna, Italy
-
- P334** **Medication-Induced Delirium in Older People Hospitalized in General Wards Care: A Systematic Review**
Marques Cavalcante-Santos Lincoln, University of São Paulo, Brazil
-
- P335** **Applying a Launch Excellence Framework in Patient Safety**
Strother Rachel, BMS, USA
-

-
- P336** [Development of a Framework for the Integration of Two Major Biopharmaceutical Organizations and Guidance for Pharmacovigilance](#)
Di Menno Di Bucchianico Roberta, Bristol Myers Squibb, Italy
-
- P337** [Let's Make a PV Agreement: Three Solutions You Can Use to Enhance Your PVA Process](#)
Kilgour-Christie Jean, Novartis Pharma GmbH, Germany
-
- P338** [Facial Paralysis Associated with Pembrolizumab Use: Adverse Events- Signal Review](#)
Alamri Roaa, Saudi Food and Drug Authority, Saudi Arabia
-
- P339** [Perception and Behavior towards Risk Information in the Patient Information Leaflet in Saudi Arabia](#)
Alamri Roaa, Saudi Food and Drug Authority, Saudi Arabia
-
- P340** [Sexual Disorders with Selective Serotonin Reuptake Inhibitors: A Comparative Study](#)
Trenque Thierry, CHU Reims, France
-
- P342** [Future of Healthcare and Opportunities/Challenges for Pharmacovigilance in the Digital Age](#)
Ghosh Rajesh, Genentech/Roche, USA
-
- P343** [The Global Pharmacovigilance Professional Certification \(GPPC\)](#)
Petráček Jan, Institute of Pharmacovigilance, Czech Republic
-
- P345** [PVReg: A Comprehensive Global Pharmacovigilance Requirement Profiling and Analysis System](#)
Delumeau Jean-Christophe, Institute of Pharmacovigilance, Czech Republic
-
- P346** [A Comprehensive Global Repository of Pharmacovigilance-Relevant Regulations](#)
Delumeau Jean-Christophe, Institute of Pharmacovigilance, Czech Republic
-
- P347** [Pilot Implementation of the Global Pharmacovigilance Professional Certification \(GPPC\)](#)
Delumeau Jean-Christophe, Institute of Pharmacovigilance, Czech Republic
-
- P348** [Proactive Drug Safety Monitoring of Adverse Drug Events in Saudi Arabia: 2021 Experience](#)
Al-Fadel Nouf, Saudi Food and Drug Authority, Saudi Arabia
-
- P349** [Sertraline and the Potential Risk of Pulmonary Eosinophilia Drug-Induced](#)
Al-Fadel Nouf, Saudi Food and Drug Authority, Saudi Arabia
-

- 
-
- P350** **The Antidepressant Effects of Hypoglycaemic Agents: New Insights from an Analysis of the FDA Adverse Event Reporting System (FAERS) Database**
Carnovale Carla, Università degli Studi di Milano, Italy
-
- P351** **Drug-Induced Canaliculitis: An Observational Postmarketing Study**
Trenque Thierry, CHU Reims, France
-
- P352** **Spontaneous Reports vs Cohort Event Monitoring: Differences in Collecting Information on Adverse Drug Reactions of Non-Vitamin K Oral Anticoagulants**
Von Kreijfelt Gabriëlla, The Netherlands Pharmacovigilance Centre Lareb, Netherlands
-
- P353** **Eritrea's Experience in Safety Monitoring of Mass Administration of Praziquantel**
Bahta Merhawi, Ministry of Health, Eritrea
-
- P354** **Pharmacovigilance in no Profit Clinical Trial: Duties and Responsibilities for the Research Team**
Cenna Rosita, S.C. Oncoematologia Pediatrica, Presidio Infantile Regina Margherita – A.O:U: Città della salute e della Scienza di Torino, Italy
-
- P355** **Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System**
Raschi Emanuel, Alma Mater Studiorum – University of Bologna, Italy
-
- P356** **Marketing Authorization Holders: The Pharmacovigilance Performance Pattern According to their Geographic Classification**
Arafah Amal, Saudi Food and Drug Authority, Saudi Arabia
-
- P357** **Exploring Subpopulation Signal Detection Methods on Spontaneous Adverse Event Reporting Databases**
Candore Gianmario, Bayer, Germany
-
- P358** **Pharmacovigilance Capacity Building in Indonesia 2017–2021: Overview and Impact Trend Analysis**
Wangge Grace, Monash University Indonesia, Indonesia
-
- P359** **Drug Safety in Geriatric Patients and the Need for a New ISoP Special Interest Group**
D'souza Joan, Institute of Pharmacovigilance, Switzerland
-
- P360** **Developing Training Material for Community Health Workers on Adverse Drug Reaction Reporting: A Pilot Project**
Viljoen Michelle, University of the Western Cape, South Africa
-

-
- P362** **Pediatric Drug Safety Surveillance: A Ten-years Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy**
Leporini Christian, "Magna Graecia" University of Catanzaro, Italy
-
- P363** **Educational Interventions to Improve the Report, Attitude, and Knowledge of Adverse Drug Reactions in Healthcare Professionals: Systematic Review and Meta-Analysis**
Cervantes-Arellano Monica, Universidad Nacional Autónoma de México (UNAM), Mexico
-
- P364** **International Harmonization of Good Pharmacovigilance Practices: Impact on Brazil**
Capucho Helaine, Brazilian, Brazil
-
- P365** **Use of Psychotropic Medications before and after Self-Harm in a Regional Cohort of Older Adults Aged 75+**
Hedna Khedidja, University of Gothenburg, Sweden
-
- P366** **Interdisciplinary Collaboration for Benefit-Risk Assessment Planning During the Medical Product Lifecycle: Results from a Survey**
Edwards Brian, Husoteria Ltd, United Kingdom
-
- P368** **Pharmacovigilance Challenges in Cannabis Medicinal Products – A Narrative Review**
Matos Cristiano, Instituto Politécnico De Coimbra, ESTESC-Coimbra Health School, Portugal
-
- P369** **Occurrence and Characteristics of Linezolid Toxicity in Clinical Practice: Interim Analysis of a Prospective Multicentric Study**
Thirot Helene, UClouvain, Belgium
-
- P370** **Developing Practical Pharmacovigilance Skills at a Distance: Description and Evaluation of UMC's Instructor-Led Online Learning**
Jastrebova Nadja, Uppsala Monitoring Centre, Sweden
Elki Sollenbring, Uppsala Monitoring Centre, Sweden
-
- P372** **An Exceptional DRESS syndrome to Potaba with Positive Patch Test**
Lakhoua Ghozlane, Université Tunis el Manar Faculté de médecine de Tunis / Unité de recherche UR17ES12, Tunisia
-
- P373** **Has Piperine a Role to Play Against Breast Cancer?**
Joaquim João José, University of Salamanca, Portugal
-
- P374** **Is There an Important Role Played by Thiamine (Vit B1) in Alzheimer's Disease?**
Joaquim João José, University of Salamanca, Portugal
-

- 
-
- P376** **A System for Reporting Adverse Drug Reactions to Emergency: Pilot Project**
Donadu Matthew Gavino, Sassari University Hospital, Italy
-
- P377** **What's up in Celiac Disease Treatment?**
Joaquim João José, University of Salamanca, Portugal
-
- P378** **Current Pharmacovigilance Outsourcing Practices in Arab Countries**
Abdeldayem Ibrahim, Arriello s. r. o, Egypt
-
- P379** **Outsourcing of Pharmacovigilance Activities for Pharmaceutical Industries in Brazil**
Lauton Letícia, Safety One Specialized Services in Pharmacovigilance, Brazil
-
- P380** **Safety of Antiangiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-analysis**
Spini Andrea, Azienda Ospedaliera Universitaria Senese, Italy
-
- P381** **Pharmacovigilance in Hospital: Monitoring Reports of Adverse Drugs and Vaccines Reactions Collected in an Active Pharmacovigilance Project**
Impagliatelli Rosa, University of Pisa, Italy
-
- P382** **Drug Use in Patients before and after Starting Chronic Dialysis, Lazio Regional Dialysis and Transplant Registry, 2008-2020**
Kirchmayer Ursula, Lazio Regional Health Service, ASL Roma1, Italy
-
- P383** **ICSR and Pharmacovigilance Data: Challenges for Pharmaceutical Companies**
Lorenzi Silvia, PQE Group, Italy
-
- P385** **Real-World Efficacy and Safety of Off-Label Use of Immune Checkpoint Inhibitors (ICI) in Cancer: A Retrospective Cohort Study in Qatar**
Abaza Seif, Hamad Medical Corporation, Qatar
-
- P388** **Pharmacovigilance Funding Landscape in Africa – A Survey**
Isah Ambrose, University of Benin / University of Benin Teaching Hospital, Nigeria
-
- P389** **Characterization of Factors Associated with Long-Term Prescription Opioid Use in Support of Risk Mitigation Strategies in the Non-Cancer Population**
Castillon Genaro, YolaRX Consultants, Canada
-
- P390** **Post-Marketing Safety of Innovative Drugs: Analysis of Pembrolizumab Related ADRs in a University Hospital**
Impagliatelli Rosa, University of Pisa, Italy
-
- P391** **Analysis of the Reports of Suspected Adverse Drugs Reactions of 2021 in a Tuscan University Hospital**
Impagliatelli Rosa, University of Pisa, Italy
-

P392 Knowledge, Attitude, and Practice Regarding Pharmacovigilance among Health Care Professionals of Nepal: A Cross-Sectional Study
Gyanwali Pradip, Nepal Health Research Council, Nepal

P394 Developing Kidney-Specific Causality Assessment Tool
Gülmez Sinem Ezgi, Koç University School of Medicine, Turkey

Flash Presentation listing

On-Site No. / Poster No. / Time / Paper Title / Presenter

SESSION 1 POSTER FLASH PRESENTATION WEDNESDAY 21 SEPTEMBER

FP2 P039 / 12:50–12:55
Smart Safety Surveillance of Vaccines in Mass Immunization Campaigns: Eritrea's Evolving Experience in a Nutshell
Debesai Merhawi, Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Ministry of Health, Eritrea

FP4 P091 / 12:55–13:00
Association between SARS-CoV-2 Vaccines and Myo- and Pericarditis; a Large Observational Study Using Electronic Healthcare Data from Four European Countries
Riera-Arnau Judit, Hospital Universitari Vall Hebron, Spain

FP6 P092 / 13:00–13:05
Covid-Vaccine-Monitor: a Cohort Event Monitoring Safety Study of COVID-19 Vaccines in Twelve European Countries
Riefolo Fabio, Teamit Institute S.L., Spain

FP8 P093 / 13:05–13:10
How the United States' Vaccine Adverse Event Reporting System (VAERS) Database Has Been Used to Study SARS-CoV-2 Vaccine Safety
Weiss Sheila, Exponent, USA

FP10 P094 / 13:10–13:15
Real-life Safety of Oral Antivirals for COVID19: a Retrospective Cohort Study
Pivato Lisa, University Hospital of Padova, Italy
